FY2027 Earnings Estimate for VIGL Issued By William Blair

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Research analysts at William Blair issued their FY2027 EPS estimates for Vigil Neuroscience in a note issued to investors on Thursday, May 22nd. William Blair analyst M. Minter anticipates that the company will earn ($1.78) per share for the year. William Blair has a “Hold” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

Vigil Neuroscience (NASDAQ:VIGL) last posted its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04.

Several other research analysts have also recently issued reports on VIGL. Citizens Jmp cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday. JMP Securities reaffirmed a “market perform” rating on shares of Vigil Neuroscience in a research report on Thursday. HC Wainwright cut their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Guggenheim set a $8.00 target price on Vigil Neuroscience and gave the stock a “neutral” rating in a report on Thursday. Finally, Citigroup downgraded Vigil Neuroscience to a “market perform” rating in a report on Thursday. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Vigil Neuroscience has an average rating of “Hold” and a consensus price target of $13.00.

Vigil Neuroscience Stock Up 0.1%

NASDAQ VIGL opened at $7.89 on Friday. The firm has a market capitalization of $368.24 million, a PE ratio of -3.83 and a beta of 1.90. The stock’s 50 day moving average is $2.19 and its 200 day moving average is $2.30. Vigil Neuroscience has a twelve month low of $1.31 and a twelve month high of $7.95.

Institutional Investors Weigh In On Vigil Neuroscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in VIGL. Cubist Systematic Strategies LLC lifted its holdings in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after buying an additional 8,358 shares during the period. Jane Street Group LLC purchased a new stake in Vigil Neuroscience during the fourth quarter valued at $83,000. Barclays PLC increased its position in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after acquiring an additional 19,436 shares during the last quarter. Northern Trust Corp lifted its holdings in Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after acquiring an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP lifted its holdings in Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after acquiring an additional 49,000 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.